U.S. Markets closed

Perrigo Company plc (PRGO)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
77.27-0.42 (-0.54%)
At close: 4:01PM EDT
People also watch
MYLENDPALXNTEVAREGN
  • H
    Horowitz
    Horowitz

    SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M / 17 FDA approved products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..GLTA

    Sonoma Pharma (Nasdaq: SNOA)

    Market Cap: 22.1 Million
    Cash: $12.6 Million
    Price: $5.15

    Shares Out : 4.3 Million

    Presentation
    http://ir.sonomapharma.com/common/download/download.cfm?companyid=ocls&fileid=945547&filekey=F57B6874-6CD1-4205-A160-8E08BBB7A928&filename=SonomaPharma_Investor_presentation_13June2017.pdf

    Fact Sheet
    http://files.shareholder.com/downloads/OCLS/4977255852x0x231236/39d834a3-8462-40ee-8650-e0945b6facd5/Sonoma_Fact_Sheet.pdf

    Driving to commercial EBITDAS breakeven, without dilution

    Grow current product portfolio with all sales people

    •Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment
    •Mondoxyne for severe acne –launched late 2015
    •Ceramax for skin repair in atopic dermatitis–launched in April 2016
    •SebuDerm for seborrhea dermatitis –launched in November 2016

    Launch 3 New Products –our product pipeline –one every other quarter

    •Launching Loyon–Fall 2017
    •Ceramax in foam and gel forms –Q4 2017 & Q1 2018

    Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.

    We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.

  • B
    Bob
    Bob
    Whoever sold August covered calls @$80 get to keep their stock and hope for an even higher price!
  • A
    Ashley
    Ashley
    I think PRGO is due for a pullback. What are your thoughts? Ive been struggling with this stock lately. Some of my other trades have been from Awe-Som.e.Sto-cks. which are working out pretty well.
  • M
    Makayla
    Makayla
    The scenarios are quite interesting at current levels for PRGO. Im not sure about you guys but awe-some*sto-cks has provided me with some pretty good trade ideas. I messed up executing some of them but thats on me.
  • I
    ICDC WEB
    ICDC WEB
    up over $7 pre-market. Wow!!
  • A
    Anonymous
    Anonymous
    UVXY made 25 % today
  • W
    Weyrtuyww
    Weyrtuyww
    I drew my line in the sand on this at $200/sh.....sold at $199/sh about 2 years ago as you idiots turned down Mylan's offer. When opportunity knocks you gotta open the door...that's what my aunt Myrtle use to say
  • A
    Anna
    Anna
    The trading setup for PRGO looks very enticing. Ive been struggling with this stock lately. Some of my other trades have been from awe-some*sto-ck*s which are working out pretty well.
  • D
    Darren
    Darren

    Buy BCDA!! It ready to move higher.
    https://finance.yahoo.com/news/biocardia-completes-roll-cohort-pivotal-120000400.html

    BioCardia Completes Roll-in Cohort in Pivotal Phase III CardiAMP Heart Failure Trial
    BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced completion of treatment for the 10-patient roll-in cohort for the pivotal Phase III CardiAMP Heart Failure Trial.
    finance.yahoo.com
  • Q
    Quant Scanner
    Quant Scanner

    [!] Option traders pay a visit to CreditSpreads.io, totally free live list of mathematically gainful option credit spreads for the coming 4 weeks, sometimes including spreads for PRGO! High probability option credit spreads supply an approach to trade with determined risk and the max profit received up front. CreditSpreads.io targets exclusively the credit spreads which satisfy its strict criteria for risk and profit, and contributes to continued profitability by alerting you of any impending catalysts that could affect the trade. http://www.creditspreads.io

    CreditSpreads.io
    Sustainable, high probability, defined risk stock option trading opportunities.
    www.creditspreads.io
  • Z
    Zoe
    Zoe
    I think PRGO is due for a pullback. What are your thoughts? check out awe*some*stock*s, its a pretty reliable service. of course you have to do your own due diligence, but they generally point you in the right direction.
  • P
    Pharmaherooooooo
    Pharmaherooooooo

    KTOV = Mcap $16 Mil /Cash $17 Mil /Low float O/S 10 M / NDA submission for Big Drug this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension
    https://baystreet.ca/articles/research_reports/lifesci/Kitov062717.pdf

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets

    “KIT-302 has the potential to address the multi-billion dollar market for the treatment of osteoarthritis pain and hypertension with one drug that reduces patients’ risk of suffering a heart attack or stroke, while also reducing cost for payers. There is currently no single medication on the market that treats both osteoarthritis pain and hypertension and thus, KIT-302 will be the only NSAID indicated both to treat pain and to reduce the risk of heart attack, stroke and death.”

    Pain medications for osteoarthritis account for billions of dollars in annual sales globally. Most pain medications for osteoarthritis, including celecoxib which had global sales of $2.7 billion in 2014, are non-steroidal anti-inflammatory drugs (NSAIDs) which have the side effect of elevating blood pressure, and increasing the risk of heart attacks, strokes and death. Of the 27 million Americans who live with osteoarthritis, 13.5 million also suffer from hypertension, which also increases the risk of heart attack, stroke, and death.

  • S
    Stephanie
    Stephanie
    The trading setup for PRGO looks very enticing. if you guys have questions you should ask awe.SOME-StockS. They often respond to my emails which is helpful.
  • K
    Kevon
    Kevon

    http://jcharlesassets.com/opiant-pharmaceuticals/?s=PRGO has an alert for $PRGO. Did anyone happen to see it as well? Looking for some good positive information from the company! "hhse" Investing day trading.

    Best MicroCap, Small Cap and Emerging Stocks to Buy - J Charles Assets
    We search for the smart new growing companies to invest in with stock deals to watch in pharmacuetical and digital verticals.
    jcharlesassets.com
  • A
    Anonymous
    Anonymous

    Option traders take a look at CreditSpreads.io, absolutely free live table of mathematically gainful option credit spreads for the following 4 weeks, sometimes including spreads for PRGO! High-probability option credit spreads provide a strategy to trade with defined risk and the maximum profit received up front. CreditSpreads.io lazer-targets solely the option spreads which satisfy its stringent criteria for risk and profit, and contributes to continued profitability by telling you of any expected events that could affect the trade. http://www.creditspreads.io

    CreditSpreads.io
    Sustainable, high probability, defined risk stock option trading opportunities.
    www.creditspreads.io
  • F
    Frances
    Frances

    Did anyone else see $PRGO report from http://jcharlesassets.com/opiant-pharmaceuticals/?s=PRGO ? It had some interesting information. "rht" Day trading making money.

    Best Penny, OTC Stocks and Dividend Stocks to Buy - J Charles Assets
    We search for the smart new growing companies to invest in with stock deals to watch in pharmacuetical and digital verticals.
    jcharlesassets.com
  • C
    Cassandra
    Cassandra
    The upside potential for PRGO just got a whole lot more interesting. Do you guys find it difficult to know when to buy or sell something? I prefer to get my stocks from awesome_stocks.
  • s
    shep21998
    shep21998
    Did anyone have part of the dividend withheld with the payment today. Ireland doesn't withhold dividends so I am wondering what the deal is. The only two countries I know that don't withhold are ireland and the UK
  • s
    shep21998
    shep21998
    l am not planning to pay the Irish government for holding this stock so when the dividend got withheld today, that does it. Medtronic had a deal with Ireland that the dividend would not get withheld, I guess Perrigo wasn't smart enough to work that out and neither was Johnson Control. Johnson Control AFTER AUG 2017 will have 20% of the div. withheld by the Irish, so that stock will get the boot after I get that div.
  • D
    David
    David
    If you ask me , hendrikson didnt retire. he was removed and maybe there already is a candidate. they just want to make this change elegantly without causing too much waves.